161 related articles for article (PubMed ID: 20533374)
1. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
[TBL] [Abstract][Full Text] [Related]
2. Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats.
Katsumi H; Nakatani M; Sano J; Abe M; Kusamori K; Kurihara M; Shiota R; Takashima M; Fujita T; Sakane T; Hibi T; Yamamoto A
Int J Pharm; 2010 Nov; 400(1-2):124-30. PubMed ID: 20816731
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats.
Katsumi H; Liu S; Tanaka Y; Hitomi K; Hayashi R; Hirai Y; Kusamori K; Quan YS; Kamiyama F; Sakane T; Yamamoto A
J Pharm Sci; 2012 Sep; 101(9):3230-8. PubMed ID: 22467424
[TBL] [Abstract][Full Text] [Related]
4. [Development of a novel transdermal delivery system of alendronate, a nitrogen containing bisphosphonate, using a new type of hydrophilic patch and dissolving microneedle arrays].
Katsumi H
Yakugaku Zasshi; 2014; 134(3):427-31. PubMed ID: 24584024
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Li B; Huang G; Ma Z; Qin S
Acta Biochim Pol; 2020 Jun; 67(2):173-179. PubMed ID: 32558528
[TBL] [Abstract][Full Text] [Related]
6. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats.
Katsumi H; Takashima M; Sano J; Nishiyama K; Kitamura N; Sakane T; Hibi T; Yamamoto A
J Pharm Sci; 2011 Sep; 100(9):3783-92. PubMed ID: 21567410
[TBL] [Abstract][Full Text] [Related]
7. Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.
Boche M; Pokharkar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1078-1089. PubMed ID: 29987552
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
10. Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Kong F; Jia B; Cui P; Wang D
Acta Biochim Pol; 2019 Dec; 66(4):463-467. PubMed ID: 31846272
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
13. Relative effects of exercise training and alendronate treatment on skeletal muscle function of ovariectomized rats.
Widrick JJ; Fuchs R; Maddalozzo GF; Marley K; Snow C
Menopause; 2007; 14(3 Pt 1):528-34. PubMed ID: 17415018
[TBL] [Abstract][Full Text] [Related]
14. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
15. Alendronate: a bisphosphonate for treatment of osteoporosis.
Kirk JK; Spangler JG
Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats.
Ballester I; Daddaoua A; López-Posadas R; Nieto A; Suárez MD; Zarzuelo A; Martínez-Augustin O; Sánchez de Medina F
Br J Pharmacol; 2007 May; 151(2):206-15. PubMed ID: 17375077
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans.
Choi A; Gang H; Whang J; Gwak H
Drug Deliv; 2010 May; 17(4):249-54. PubMed ID: 20214414
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
19. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
[TBL] [Abstract][Full Text] [Related]
20. Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats.
Giro G; Gonçalves D; Sakakura CE; Pereira RM; Marcantonio Júnior E; Orrico SR
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Feb; 105(2):162-7. PubMed ID: 18230387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
